Table 3.
Diagnostic outcomes of five patients diagnosed with mosquito-borne disease, from July to October 2018, Czech Republic.
| Case | Days Tested | WNV PCR (S,WB, CSF,U) |
IgM 1 WNV ELISA Euroimmun 2 WNV ELISA Focus 3 WNV IIFT Euroimmun |
IgG 1 WNV ELISA Euroimmun 2 WNV ELISA Focus 3 WNV IIFT Euroimmun |
WNV VNT (titre) |
4 TBEV IgM ELISA (IP) |
4 TBEV IgG ELISA (IP) |
4 TBEV IgG avidity (%) | TBEV VNT (Titre) |
USUV VNT (Titre) |
Case Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 23.10. 2018 | 0.91 (eq.) 1 1.57 (pos.) 2 |
3.49 (pos) 1 | 512 (pos.) | neg. | 12.67 (pos.) | 100% | 32 (pos.) | 128 (pos.) | WNV confirmed | |
| 2 | 18.8. 2018 | >20 (pos.) 3 | >20 (pos.) 3 | 4 (eq.) | neg. | neg. | neg. | WNV confirmed | |||
| 20.8. 2018 | S-inhib. CSF-pos. |
>20 (pos.) 3 | >20 (pos.) 3 | 8 (pos.) | |||||||
| 24.8. 2018 |
S-pos. CSF-neg. |
>20 (pos.) 3 | >20 (pos.) 3 | 16 (pos.) | |||||||
| 28.8. 2018 | U-pos. | ||||||||||
| 3 | 3.10. 2018 | S,CSF,U-neg. |
3.11 (pos.) 1 7.22 (pos.) 2 >20 (pos.) 3 |
1.10 (eq.) 1 1.02 (eq.) 2 >20 (pos.) 3 |
64 (pos.) | neg. | neg. | neg. | 16 (pos.) | WNV confirmed | |
| 4.10. 2018 | WB-pos. | ||||||||||
| 10.10. 2018 |
WB-pos. S,U-neg. |
5.63 (pos.) 2 | 2.28 (pos.) 2 | 128 (pos.) | neg. | neg. | neg. | 32 (pos.) | |||
| 8.11. 2018 |
WB-pos. S,U-neg. |
1.65 (pos.) 1 | 2.82 (pos.) 1 | 32 (pos.) | neg. | 1.81 (pos.) | 33 % | neg. | 8 (pos.) | ||
| 13.12. 2018 |
WB-pos. U-neg. |
1.61(pos.) 1 | 3.13 (pos.) 1 | 32 (pos.) | neg. | 2.41 (pos.) | 36 % | neg. | neg. | ||
| 15.2. 2019 | WB-pos.;U-neg. | ||||||||||
| 4 | 18.9. 2018 | S-neg. |
2.36 (pos.) 1 5.27 (pos.) 2 >500 (pos.) 3 |
neg. 1 neg. 2 20 (pos.) 3 |
neg. | neg. | neg. | neg. | neg. | WNV confirmed | |
| 24.9. 2018 | S-neg. U-pos. |
2.90 (pos.) 1 6.39 (pos.) 2 500 (pos.) 3 |
1.31 (pos.) 1 1.26 (pos.) 2 >20 (pos.) 3 |
8 (pos.) | 0.96 (eq.) | 1.19 (pos.) | 38 % | neg. | 4 (eq.) | ||
| 1.10. 2018 | S, U-neg. |
3.69 (pos.) 1 6.28 (pos.) 2 |
2.12 (pos.) 1 2.13 (pos.) 2 |
64 (pos.) | neg. | 2.18 (pos.) | 22 % | neg. | 16 (pos.) | ||
| 4.10. 2018 | WB-pos. | ||||||||||
| 19.10. 2018 | WB, U-neg. | 3.10 (pos.) 1 | 3.16 (pos.) 1 | 64 (pos.) | neg. | 2.75 (pos.) | 20 % | neg. | 4 (eq.) | ||
| 25.1. 2019 | WB neg. U-pos. |
neg. 1 | 3.05 (pos.) 1 | 32 (pos.) | neg. | 2.10 (pos.) | 43 % | neg. | neg. | ||
| 5 | 1.10. 2018 | S, CSF-neg. | neg. 1,2,3 | neg. 1,2,3 | neg. | neg. | neg. | neg. | 16 (pos.) | USUV | |
| 5.10. 2018 | WB, U-neg. | neg. 1,2 >20 (pos.) 3 |
neg. 1,2,3 | ||||||||
| 10.10. 2018 |
1.37 (pos.) 1 20 (pos.) 3 |
neg. 1 20 (pos.) 3 |
16 (pos.) | neg. | neg. | neg. | 256 (pos.) | ||||
| 25.10. 2018 | neg. 2 | 0.93 (eq.) 1 |
Legend: S-serum, WB-whole blood, CSF-cerebrospinal fluid, U-urine, IP-positivity index, IIFT-indirect immunofluorescence, VNT-virus neutralization test, pos.-positive, neg.-negative, eq.-equivocal, inhib.-inhibition; Reference values for WNV ELISA Euroimmun IgG and IgM (IP): <0.80 negative, 0.80–1.10 equivocal, >1.10 positive; Reference values for WNV ELISA Focus IgG (IP) <1.30 negative, 1.30–1.50 equivocal, >1.50 positive; Reference values for WNV ELISA Focus IgM (IP) <0.90 negative, 0.90–1.10 equivocal, >1.10 positive; Reference values for TBEV ELISA IgG and IgM (IP): <0.90 negative, 0.90–1.10 equivocal, >1.10 positive; Reference values for TBEV ELISA IgG avidity (%): <40 % low, 40–60 equivocal, >60 high; Reference values for WNV IIFT Euroimmun: <20 negative, ≥20 positive; Reference values for VNT( titre): <4 negative, 4 equivocal, >4 positive. All positive values are highlighted in bold. 1 West Nile Virus ELISA IgG, IgM ELISA, Euroimmun, Lübeck, Germany (Cat Nr. EI 2662-9601 G,M); 2 West Nile Virus ELISA IgG, IgM capture Dx SelectTM ELISA, Focus Diagnostics, Cypress, California, U.S. (Cat Nr EL 0300 G,M); 3 West Nile Virus IgG, IgM IIFT, Euroimmun, Lübeck, Germany (Cat Nr. FI 2662-1005 G,M); 4 ELISA-Viditest anti-TBEV IgG, IgG avidity and IgM, Vidia, Vestec, Czech Republic (Cat Nr. OD-170, OD-194).